globally. Available treatment options are often insufficient and new
approaches are much needed. Umeå-based Lipum develops SOL-116, a new way to
treat inflammation. The company expects to conclude the phase I study by late
2024 and plans for the next development step.
Västra Hamnen initiates research coverage of Lipum with a fair value of SEK
10.81 per share.
Aktuellt
SENASTE
